---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-040171"
form_type: "8-K"
ticker: null
cik: "0001845459"
company_name: "NKGen Biotech, Inc."
filed_at: "2023-03-31T23:59:59+00:00"
generated_at: "2026-06-17T08:26:04.820720+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Graf Acquisition Corp. IV restates Q2 and Q3 2022 financials; material weakness in internal controls

## Summary
- Non-reliance on previously issued unaudited interim financials for Q2 and Q3 2022 due to accounting error on deferred underwriting fee waiver.
- Error: waiver of deferred underwriting fee should have been credited to stockholder's deficit, not recognized as extinguishment gain in operations.
- Material weakness in internal control over financial reporting identified as of December 31, 2022.
- Restatement expected in annual report on Form 10-K for year ended December 31, 2022; no impact on cash or trust account.

## SEC filing metadata
- accession: 0001104659-23-040171
- form_type: 8-K
- cik: 0001845459
- company_name: NKGen Biotech, Inc.
- filed_at: 2023-03-31T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 4.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1845459/000110465923040171/0001104659-23-040171-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1845459/000110465923040171/tm2311107d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-040171
- JSON: https://secwatch.observer/filing/0001104659-23-040171.json
- Plain text: https://secwatch.observer/filing/0001104659-23-040171.txt

## Key facts
- Auditor Changes
  NKGen Biotech, Inc. reported that prior financial statements should not be relied upon.
  - Action: non reliance
  source text: On March 28, 2023, the Company’s management and the audit committee of the Company’s board of directors (the “Audit Committee”) concluded that the Company’s previously issued unaudited interim financial statements included in the 10-Qs should no longer be relied upon and that it is appropriate to restate the 10-Qs.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1845459/000110465923040171/0001104659-23-040171-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.